Go Deep
Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -12,862 | -10.1 | 72.99 | 0.00 | 1,476.12 |
| Oct 2026 | -12,612 | -10.1 | 72.52 | 0.00 | 1,462.19 |
| Oct 2026 | -12,412 | -10.1 | 72.14 | 0.00 | 1,454.80 |
| Oct 2026 | -10,486 | -9.5 | 68.52 | 0.00 | 1,378.10 |
| Oct 2026 | -12,537 | -9.9 | 71.63 | 0.00 | 1,442.16 |
| Oct 2026 | -15,114 | -10.6 | 76.48 | 0.00 | 1,539.82 |
| Oct 2026 | -15,939 | -10.8 | 78.03 | 0.00 | 1,567.23 |
| Oct 2026 | -13,212 | -10.1 | 72.90 | 0.00 | 1,461.17 |
| Oct 2026 | -14,588 | -10.5 | 75.49 | 0.00 | 1,519.36 |
Greenwich LifeSciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -3,948,675.0 | -5,657,137.0 | -7,922,733.0 | -4,151,845.0 |
| EPS | -0.3 | -0.4 | — | -0.3 |
Greenwich LifeSciences, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -19,358,218.0 | -17,414,219.0 | -8,891,803.0 | -7,825,237.0 |
| EPS | -1.4 | -1.3 | -0.7 | -0.6 |
Greenwich LifeSciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 6,178,021.0 | 4,093,769.0 | 6,994,815.0 | 13,477,029.0 | — |
| Total Liabilities | 5,824,804.0 | 3,185,143.0 | 294,406.0 | 262,905.0 | — |
| Total Equity | 353,217.0 | 908,626.0 | 6,700,409.0 | 13,214,124.0 | — |
Owes vs Owns
Greenwich LifeSciences, Inc. owed $0.65 for every $1 it owned in Jun 2026, up from $0.02 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.65× | 0.94× | 0.78× | 0.04× | 0.02× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Greenwich LifeSciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 100.0%
How it's funded — Dec 2025
Payables 78.9%Other liabilities 15.4%Shareholders' equity 5.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 6.2 | 4.1 | 7.0 | 13.5 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 4.9 | 2.8 | 0.3 | 0.2 |
| Other liabilities | 1.0 | 0.4 | 0.0 | 0.0 |
| Shareholders' equity | 0.4 | 0.9 | 6.7 | 13.2 |
| Net tangible assets | 0.4 | 0.9 | 6.7 | 13.2 |
Greenwich LifeSciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -9,913,453.0 | -7,266,543.0 | -6,478,602.0 | -6,200,027.0 | — |
| Financing Activities | 11,999,484.0 | 4,369,109.0 | 0.0 | -7,536,216.0 | — |